Open-source automated insulin delivery systems for the management of type 1 diabetes during pregnancy

2021 ◽  
Vol 14 (9) ◽  
pp. e243522
Author(s):  
Khulood Bukhari ◽  
Rana Malek

A 40-year-old woman used an open-source automated insulin delivery system to manage her type 1 diabetes (T1D) prior to conception. The code for building the iPhone application called ‘Loop’ that carried the software for the hybrid closed-loop controller was available online. Her glycated hemoglobin before conception was 6.4%. Between 6 and 12 weeks gestation, she spent 66% time-in-range (TIR), 28% time-above-range (TAR) and 6% time-below-range (TBR). Between 18 and 24 weeks gestation, she spent 68% TIR, 27% TAR and 5% TBR. During her third trimester, she spent 72% TIR, 21% TAR and 7% TBR. She delivered a healthy infant with no neonatal complications. Clinicians should be aware of this technology as it gains traction in the T1D community and seeks Food and Drug Administration approval.

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1065-P ◽  
Author(s):  
ANASTASIOS KOUTSOVASILIS ◽  
ALEXIOS SOTIROPOULOS ◽  
ANASTASIA ANTONIOU ◽  
VASILIOS KORDINAS ◽  
DESPINA PAPADAKI ◽  
...  

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 976-P
Author(s):  
AHMED H. ELDIB ◽  
SHAHEEN TOMAH ◽  
SHILTON E. DHAVER ◽  
HANNAH GARDNER ◽  
MHD WAEL TASABEHJI ◽  
...  

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 121-LB
Author(s):  
AHMED H. ELDIB ◽  
ELENA TOSCHI ◽  
NOOR MAHMOUD ◽  
MHD WAEL TASABEHJI ◽  
SAHAR ASHRAFZADEH ◽  
...  

2021 ◽  
Vol 1 (6) ◽  
Author(s):  
Health Technology Assessment Team

The CADTH Health Technology Expert Review Panel (HTERP) suggests that hybrid closed-loop insulin delivery (HCL) systems hold promise for the care of people with type 1 diabetes. HTERP considers that, at present, there are insufficient long-term data on clinically relevant and patient-important outcomes to recommend how extensive the role of HCL systems should be in care. HTERP recommends the collection of robust and comparative data for consideration of future reassessments that compare HCL systems to existing insulin delivery and glucose monitoring methods in terms of glycated hemoglobin (hemoglobin A1C); time-in-range; time above and below range; glycemic variability; quality of life; patient, parent or caregiver, and health care provider satisfaction; diabetes-related complications; discontinuation rates; and health system impact. Robust data are collected in well-designed comparative studies that are, among other considerations, of sufficient duration to ensure a clinically meaningful outcome assessment.


JAMA ◽  
2016 ◽  
Vol 316 (13) ◽  
pp. 1407 ◽  
Author(s):  
Richard M. Bergenstal ◽  
Satish Garg ◽  
Stuart A. Weinzimer ◽  
Bruce A. Buckingham ◽  
Bruce W. Bode ◽  
...  

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 282-OR
Author(s):  
MARIE-ANNE BURCKHARDT ◽  
JULIE DART ◽  
GRANT J. SMITH ◽  
MARY B. ABRAHAM ◽  
NIRUBASINI PARAMALINGAM ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document